The North America Immune Checkpoint Inhibitors Market would witness market growth of 15.6% CAGR during the forecast period (2021-2027).
Immune checkpoints are a necessary aspect of the immune system's operations. Their objective is to keep the immune system from overreacting and destroying viable cells in the body. When proteins over the surface of immune cells, which are also called T cells, recognize and attach to partner proteins on other cells, such as tumor cells, immunological checkpoints get activated. These proteins are known as immune checkpoint proteins. When the checkpoint and companion proteins bind, the T cells receive an "off" signal. This may prevent the tumor from being destroyed by the immune system.
T cells are used by the immune system to fight cancer. These highly specialized cells are exceedingly powerful and can cause harm to healthy cells. Immune checkpoints, which can be positive or negative, regulate T cell activity. Positive immunological checkpoints encourage T cells to keep working, whereas negative immune checkpoints prevent T cells from doing so.
Lung cancer is the second most common cancer in the US, according to the American Cancer Society Inc's estimates for 2020, with 135,720 deaths in both men and women. According to statistics, small cell lung cancer (SCLC) accounts for about 13% of all lung cancers in the United States, while non-small cell lung cancer (NSCLC) accounts for 84 percent. This trend is expected to continue in the future, resulting in increased demand for these products.
Moreover, The CTLA-4-blocking ipilimumab for melanoma was licensed by the US Food and Drug Administration (FDA) in 2011 as the first checkpoint inhibitor immunotherapy for cancer treatment. Since then, the FDA has approved seven checkpoint inhibitors for the treatment of more than a dozen cancers.
The US market dominated the North America Immune Checkpoint Inhibitors Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $30,476.5 million by 2027. The Canada market is anticipated to grow at a CAGR of 18.2% during (2021 - 2027). Additionally, The Mexico market would witness a CAGR of 17.2% during (2021 - 2027).
Based on Application, the market is segmented into Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others. Based on Type, the market is segmented into PD-1 Inhibitor, PD-L1 Inhibitor, and CTLA-4 Inhibitor. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Immune Checkpoint Inhibitors Market is Estimated to reach $75.9 Billion by 2027, at a CAGR of 16.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Beigene Ltd., Shanghai Junshi Biosciences Co., Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Merck Group (Merck Sharp & Dohme Corp.), Sanofi S.A., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Lung Cancer
- Bladder Cancer
- Melanoma
- Hodgkin lymphoma
- Others
By Type
- PD-1 Inhibitor
- PD-L1 Inhibitor
- CTLA-4 Inhibitor
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Beigene Ltd.
- Shanghai Junshi Biosciences Co., Ltd.
- Bristol Myers Squibb Company
- GlaxoSmithKline PLC
- Eli Lilly and Company
- Merck Group (Merck Sharp & Dohme Corp.)
- Sanofi S.A.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Immune Checkpoint Inhibitors Market, by Application
1.4.2 North America Immune Checkpoint Inhibitors Market, by Type
1.4.3 North America Immune Checkpoint Inhibitors Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May – 2021, Dec) Leading Players
Chapter 4. North America Immune Checkpoint Inhibitors Market by Application
4.1 North America Lung Cancer Market by Country
4.2 North America Bladder Cancer Market by Country
4.3 North America Melanoma Market by Country
4.4 North America Hodgkin lymphoma Market by Country
4.5 North America Other Application Market by Country
Chapter 5. North America Immune Checkpoint Inhibitors Market by Type
5.1 North America PD-1 Inhibitor Market by Country
5.2 North America PD-L1 Inhibitor Market by Country
5.3 North America CTLA-4 Inhibitor Market by Country
Chapter 6. North America Immune Checkpoint Inhibitors Market by Country
6.1 US Immune Checkpoint Inhibitors Market
6.1.1 US Immune Checkpoint Inhibitors Market by Application
6.1.2 US Immune Checkpoint Inhibitors Market by Type
6.2 Canada Immune Checkpoint Inhibitors Market
6.2.1 Canada Immune Checkpoint Inhibitors Market by Application
6.2.2 Canada Immune Checkpoint Inhibitors Market by Type
6.3 Mexico Immune Checkpoint Inhibitors Market
6.3.1 Mexico Immune Checkpoint Inhibitors Market by Application
6.3.2 Mexico Immune Checkpoint Inhibitors Market by Type
6.4 Rest of North America Immune Checkpoint Inhibitors Market
6.4.1 Rest of North America Immune Checkpoint Inhibitors Market by Application
6.4.2 Rest of North America Immune Checkpoint Inhibitors Market by Type
Chapter 7. Company Profiles
7.1 AstraZeneca PLC
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Approvals and Trials:
7.2 Beigene Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 Shanghai Junshi Biosciences Co., Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.4 Bristol Myers Squibb Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 GlaxoSmithKline PLC (GSK)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Eli Lilly and Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.7 Merck Group (Merck Sharp & Dohme Corp.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Sanofi S.A.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.8.5.2 Approvals and Trials:
7.8.5.3 Acquisition and Mergers:
7.9 Merck & Co., Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. F. Hoffmann-La Roche Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Partnerships, Collaborations and Agreements:
7.10.5.2 Approvals and Trials:
TABLE 1 North America Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 2 North America Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Immune Checkpoint Inhibitors Market
TABLE 4 Acquisition and Mergers– Immune Checkpoint Inhibitors Market
TABLE 5 Approvals and Trials– Immune Checkpoint Inhibitors Market
TABLE 6 North America Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 7 North America Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 8 North America Lung Cancer Market by Country, 2017 - 2020, USD Million
TABLE 9 North America Lung Cancer Market by Country, 2021 - 2027, USD Million
TABLE 10 North America Bladder Cancer Market by Country, 2017 - 2020, USD Million
TABLE 11 North America Bladder Cancer Market by Country, 2021 - 2027, USD Million
TABLE 12 North America Melanoma Market by Country, 2017 - 2020, USD Million
TABLE 13 North America Melanoma Market by Country, 2021 - 2027, USD Million
TABLE 14 North America Hodgkin lymphoma Market by Country, 2017 - 2020, USD Million
TABLE 15 North America Hodgkin lymphoma Market by Country, 2021 - 2027, USD Million
TABLE 16 North America Other Application Market by Country, 2017 - 2020, USD Million
TABLE 17 North America Other Application Market by Country, 2021 - 2027, USD Million
TABLE 18 North America Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 19 North America Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 20 North America PD-1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 21 North America PD-1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 22 North America PD-L1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 23 North America PD-L1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 24 North America CTLA-4 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 25 North America CTLA-4 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 26 North America Immune Checkpoint Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 27 North America Immune Checkpoint Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 28 US Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 29 US Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 30 US Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 31 US Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 32 US Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 33 US Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 34 Canada Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 35 Canada Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 36 Canada Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 37 Canada Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 38 Canada Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 39 Canada Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 40 Mexico Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 41 Mexico Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 42 Mexico Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 43 Mexico Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 44 Mexico Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 45 Mexico Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 46 Rest of North America Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 47 Rest of North America Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 48 Rest of North America Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 49 Rest of North America Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 50 Rest of North America Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 51 Rest of North America Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 52 KEY INFORMATION – ASTRAZENECA PLC
TABLE 53 KEY INFORMATION – BEIGENE LTD.
TABLE 54 KEY INFORMATION – SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
TABLE 55 KEY INFORMATION – BRISTOL MYERS SQUIBB COMPANY
TABLE 56 KEY INFORMATION – GLAXOSMITHKLINE PLC
TABLE 57 KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 58 KEY INFORMATION – MERCK GROUP
TABLE 59 KEY INFORMATION – SANOFI S.A.
TABLE 60 KEY INFORMATION - MERCK & CO., INC.
TABLE 61 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 4 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May – 2021, Dec) Leading Players
FIG 5 Recent strategies and developments: Sanofi s.a.